The sales and derivative exercises appear routine (option vesting followed by same-day sales), and the dollar value is immaterial relative to CYTK's $10.6B market cap. The cluster of two C-suite officers selling at similar price levels is notable but not alarming absent material corporate events. Monitor next 8-K or press release for any product or regulatory news that might have prompted coordinated selling; otherwise, these trades are consistent with normal portfolio diversification.
CYTK drugs
CYTK drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 6 $86.49entry
- T+1 · 4mo ago −1.06%α −1.94% · $85.57
- T+5 · 4mo ago −0.49%α −1.42% · $86.07
- T+20 · 4mo ago −7.02%α −6.60% · $80.42
- T+60 · 7w ago −23.51%α −27.07% · $66.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two C-suite executives (CFO and CCO) sold a combined $1.38M in open-market shares following option exercises, with the CCO's sale ($1.29M) being the bulk. The trades occur at elevated stock prices near $85-88 and are coupled with routine derivative exercises, suggesting tax-planning or liquidity-driven selling rather than a bearish signal. However, the cluster of two top officers selling simultaneously warrants attention, though the total value is only ~0.013% of the $10.6B market cap, trivial by proportionality standards.
Key Financial Metrics
Key Facts
- CCO Andrew Callos sold 15,000 shares at $85.80 for $1.29M after exercising options at $23.26/share
- CFO Sung Lee sold 1,112 shares at $87.79 for $98K after option exercises; also sold 3,134 shares at $85 on June 29 for $266K
- Total open-market sales: ~$1.38M, approximately 0.013% of $10.6B market cap
- All derivative exercises (M) are non-cash or small-dollar conversions; combined $0 taxable option exercise proceeds
- No open-market purchases in the cluster; net direction is selling
Financial Impact
Total insider sales of ~$1.38M, representing ~0.013% of market cap, well below 0.1% proportionality threshold for material concern
Risk Factors
- If the same officers accelerate selling in larger amounts without a disclosed 10b5-1 plan, it could signal reduced confidence
- The stock trades near $85, if this is near a peak, further insider selling may increase
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CYTK-1783027190132 |
Track record
46 reports on CYTK
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers